Application of different body fluid biopsy in monitoring minimal residual disease of lung cancer postprint

Abstract: Lung cancer is one of the world's deadliest cancers, and the main reason it's difficult to conquer is that it recurs after treatment. Minimal Residual Disease (MRD), as a "bridgehead" for the recurrence of solid tumors, is described as the presence of free circulating tumor cells or other tumor cell derivatives in the biologic fluid of patients without any clinical symptoms of cancer after the treatment of the primary tumor. Recently, China also reached the first "consensus on the detection and clinical application of lung cancer MRD", aiming to evaluate the MRD status through liquid biopsy monitoring, so as to improve the postoperative individualized treatment of lung cancer patients. This paper reviewed the progress of several hot fluids (peripheral blood, urine, saliva, sputum and pleural effusion) in the detection of lung cancer MRD, and discussed their application value in guiding the precise treatment of lung cancer MRD.